Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 1 | 27 | disease | 51 | |
| 2 | 20 | subjects with | 11 | disease . | 5 |
| 3 | 2 | participants with | 9 | disease are excluded | 3 |
| 4 | 4 | patients with | 7 | disease or infection | 2 |
| 5 | 5 | subjects with an | 4 | or immunosuppressive disease . | 1 |
| 6 | 24 | has | 2 | disease or significant autoimmune related toxicity from prior immuno oncology therapy | 1 |
| 7 | 27 | any | 2 | disease with exceptions noted in protocol . | 1 |
| 8 | 13 | patients with an | 1 | disease treated hypothyroidism is permitted to enroll | 1 |
| 9 | 14 | participants must not have an | 1 | disease . subjects with resolved side effects from prior checkpoint inhibitor therapy vitiligo | 1 |
| 10 | 49 | subject with | 1 | NA | |
| 11 | 66 | history of clinically significant autoimmune disease including | 1 | NA |